A 6-thioguanine nucleotide threshold level of 400 pmol/8×10 8 erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity (American Journal of Gastroenterology (2008) 103, (3115-3122) DOI: 10.1111/j.1572-0241.2008.01743.x);A 6-thioguanine nucleotide threshold level of 400 pmol/8 × 10 8 erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity (Retraction in: American Journal of Gastroenterology (2009) 104:3 (801))

American Journal of Gastroenterology

Volumn 103, Issue 12, 2008, Pages 3115-3122

  Roblin, Xavier ^a   Biroulet, Laurent P ^b   Phelip, Jean M ^a   Nancey, Stéphane ^c   Flourie, Bernard ^c  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 THIOGUANINE NUCLEOTIDE; AZATHIOPRINE; DRUG METABOLITE; HYDROCORTISONE; INFLIXIMAB; PREDNISONE; THIOGUANINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE; NUCLEOTIDE; TIOGUANINE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; BONE MARROW TOXICITY; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERYTHROCYTE LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; TREATMENT DURATION; ULCERATIVE COLITIS; CLINICAL TRIAL; DRUG RESISTANCE; ENTERITIS; ERYTHROCYTE; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; DRUG RESISTANCE; ERYTHROCYTES; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; MIDDLE AGED; PROSPECTIVE STUDIES; THIOGUANINE; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 58149378367     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.101     Document Type: Erratum

References (30)

1. Elion GB. The pharmacology of azathioprine. Ann N Y Acad Sci 1993 685 : 401 7.
2. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003 111 : 1133 45.
3. Tidd DM, Paterson ARP. A biochemical mechanism for delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974 34 : 738 46.
4. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980 32 : 651 61.
5. Weinshilboum R. Thiopurine pharmacogenetics: Clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001 29 : 601 5.
6. Gisbert JP, Gomollón F, Cara C, et al. Thiopurine methyltransferase activity in inflammatory bowel disease. A study on 7046 Spanish patients. Med Clin (Barc) 2005 125 : 281 5.
7. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002 122 : 904 15.
8. Ansari AR, Soon SY, Arenas M, et al. Thiopurine methyltransferase activity predicts both toxicity and clinical response to azathioprine in inflammatory bowel disease: The London IBD Forum prospective study. Gastroenterology 2004 126 (Suppl 2 A1293.
9. Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990 336 : 225 9.
10. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 118 : 705 13.
11. Ansari AC, Hassan J, Duley A, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002 16 : 1743 50.
12. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001 48 : 642 6.
13. Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004 2 : 410 7.
14. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001 49 : 665 70.
15. Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease. Scand J Gastroenterol 2001 36 : 71 6.
16. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis. Gastroenterology 2006 130 : 1047 53.
17. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006 130 : 940 87.
18. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. Gastroenterology 1976 70 : 439 44.
19. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987 92 : 1894 8.
20. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990 98 : 811 8.
21. Dervieux T, Boulieu R. Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clin Chem 1998 44 : 2511 5.
22. Rossi AM, Bianchi M, Garnieri C, et al. Genotype-phenotype correlation for thiopurine S-methyltransferase healthy Italian subjects. Eur J Clin Pharmacol 2001 57 : 51 4.
23. Giverhaug T, Bergan S, Loennechen T, et al. Analysis of methylated 6-mercaptopurine metabolites in human red blood cells: Comparison of two methods. Ther Drug Monit 1997 19 : 663 8.
24. Gisbert JP, Gomollón F, Cara C, et al Thiopurine methyltransferase activity in Spain: A study of 14,545 patients. Dig Dis Sci 2007 52 : 1262 9.
25. Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004 53 : 1123 8.
26. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006 55 : 47 53.
27. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000 118 : 279 88.
28. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine and azathioprine in adult IBD patients. Am J Gastroenterol 2007 102 : 2488 94.
29. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006 55 : 1423 31.
30. Lindqvist M, Hindorf U, Almer S, et al. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 2006 25 : 1033 7.